Gene editing can repair mutations that prematurely halt protein synthesis, resulting in incomplete peptides that cause various diseases. However, other approaches achieve the same effect without ...

Last year’s chemistry Nobel prize was awarded to researchers using AI to study proteins in entirely new ways, and in 2025 ...

Research into how a father’s choices — such as diet, exercise, stress, nicotine use — may transfer traits to his children has ...

WIRED spoke with DeepMind’s Pushmeet Kohli about the recent past—and promising future—of the Nobel Prize-winning research ...

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

The following discussion is on the use of phosphite as a natural soil fungicide and bio-stimulant for early-season soil fungal control and fast plant growth. What is the difference between phosphite ...

Imagine a container of tomatoes arriving at the container terminal in Aarhus. The papers state that the tomatoes are from ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

Here are five medical breakthroughs that gave us hope in 2025. In February, a baby with a rare, often fatal genetic disorder ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...